Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Amit M. Oza(Ontario Institute for Cancer Research), Daniela Matei(Northwestern University), Geoff Hall(University of Leeds), Bristi Basu(University of Cambridge), Simone Jueliger(Plex Pharmaceuticals (United States)), Mohammad Azab(Plex Pharmaceuticals (United States)), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Merry Jennifer Markham(University of Florida), Hal W. Hirte(Juravinski Cancer Centre), Harold Keer(Plex Pharmaceuticals (United States)), Benjamin J. Schwartz(University of California, Los Angeles), Gini F. Fleming(University of Chicago Medical Center), Sharad Ghamande(Augusta University Health), John Nemunaitis(Gradalis (United States)), Ursula A. Matulonis(Dana-Farber Cancer Institute), Angeles Alvarez Secord(Duke University), Yong Hao, Susana Banerjee(Royal Marsden NHS Foundation Trust), Sarah P. Blagden(Churchill Hospital), Lynda D. Roman(University of Southern California), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Deborah K. Armstrong(Johns Hopkins University), Michael J. Birrer(University of Arkansas Medical Center), William P. McGuire(Virginia Commonwealth University), Aram Oganesian(Plex Pharmaceuticals (United States)), Sue Naim(Plex Pharmaceuticals (United States)), Patricia S. Braly(European Institute of Oncology)
Cited by 1
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k